Insider Selling: OrthoPediatrics (NASDAQ:KIDS) Director Sells $103,000.00 in Stock

Key Points

• Director David Pelizzon sold 4,000 OrthoPediatrics shares at an average price of $25.75, generating $103,000. He retained 6,897,764 shares, so the transaction reduced his ownership by just 0.06%.
• OrthoPediatrics shares traded at $24.03, near their 12-month high of $26.74. The company recently reported quarterly revenue of $70.51 million and an adjusted loss of $0.26 per share, both better than analyst expectations.
• Analyst sentiment remains favorable, with nine Buy ratings, one Hold and one Sell; the consensus rating is Moderate Buy with an average price target of $26.44. Institutional investors own approximately 69.05% of the company.

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) Director David Pelizzon sold 4,000 shares of OrthoPediatrics stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $25.75, for a total transaction of $103,000.00. Following the sale, the director owned 6,897,764 shares of the company's stock, valued at approximately $177,617,423. The trade was a 0.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

OrthoPediatrics Stock Performance

Shares of NASDAQ:KIDS traded down $0.47 during midday trading on Wednesday, reaching $24.03. The company's stock had a trading volume of 169,608 shares, compared to its average volume of 171,545. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The stock has a fifty day moving average of $21.11 and a 200 day moving average of $18.53. OrthoPediatrics Corp. has a twelve month low of $14.42 and a twelve month high of $26.74. The firm has a market capitalization of $627.42 million, a PE ratio of -14.30 and a beta of 0.98.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The business had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. On average, equities analysts expect that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Institutional Trading of OrthoPediatrics

A number of large investors have recently bought and sold shares of the business. Russell Investments Group Ltd. increased its stake in OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company's stock valued at $26,000 after purchasing an additional 1,139 shares during the period. Legal & General Group Plc purchased a new position in shares of OrthoPediatrics in the 2nd quarter valued at approximately $34,000. Northwestern Mutual Wealth Management Co. increased its holdings in shares of OrthoPediatrics by 5,226.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company's stock valued at $46,000 after purchasing an additional 2,561 shares during the period. Caption Management LLC purchased a new stake in shares of OrthoPediatrics during the third quarter worth approximately $54,000. Finally, BNP Paribas Financial Markets raised its stake in shares of OrthoPediatrics by 60.2% during the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company's stock worth $61,000 after purchasing an additional 1,235 shares during the last quarter. Institutional investors and hedge funds own 69.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on KIDS shares. Weiss Ratings upgraded OrthoPediatrics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, August 5th. Needham & Company LLC boosted their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Piper Sandler reissued an "overweight" rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Finally, BTIG Research raised their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Thursday, August 20th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $26.44.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source